[Skip to content]

Private Healthcare UK
Search our Site

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.


Alzheimer's treatment 'uses designed antibodies'

Rensselaer Polytechnic Institute (RPI) in New York

A treatment that could neutralise the harmful protein particles that cause Alzheimer's disease has been developed in the US.

Researchers at the Rensselaer Polytechnic Institute (RPI) in New York explained a process that involves designing antibodies could target the Alzheimer's protein and prevent it from leading to the onset of the condition.

The study, published in the journal Proceedings of the National Academy of Sciences, utilised the same molecular interactions that result in the Alzheimer's proteins sticking together and forming the toxic particles that are associated with the disease.

"By binding to specific portions of the toxic protein, we could test hypotheses about how to prevent or reverse cellular toxicity linked to Alzheimer's disease," explained lead researcher Peter Tessier, assistant professor of chemical and biological engineering at the RPI.

According to the Brain Research Trust, approximately 700,000 people in the UK suffer from Alzheimer's disease, including about one in 14 people aged over 65 and a sixth of over-80s.
© Adfero Ltd


Alzheimer's treatment news : 13 December 2011

Get a Quote

Care of the elderly

Get a quote now

Typical Costs

Care of the elderly

View typical costs